Speaker Detail

Dennis Purcell has been the senior managing director of Aisling Capital since 2000. The fund has $1.7 billion of assets under management. Before joining Aisling, Purcell was managing director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for over five years. While at Hambrecht & Quist, he supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Purcell is a director of Paratek Pharmaceuticals and Xanodyne Pharmaceuticals. Previously he served as a director of Aton Pharmaceuticals, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories and Valentis Inc. He has been a member of the Advisory Council at Harvard Medical School and the board of the Biotechnology Industry Association. Purcell received his M.B.A. from Harvard University and his B.S. in accounting from the University of Delaware.